Umar Mahmood, MD, PhD, currently is chief of nuclear medicine and molecular imaging at Massachusetts General Hospital and a Harvard professor of radiology, will take on the title beginning Feb. 1. 

Marcy Markes, NP, has secured representation from the Pacific Legal Foundation in an effort to overturn a state law that requires nurse practitioners to pay a physician “collaborator” if they wish to run their own practice. The lawsuit argues the regulation exists only to stifle competition.

The pharmacy chain also agreed to perform an annual audit of billed drug prices to ensure it does not run afoul of the state’s “Most Favored Nation” policy. 

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

The Class 2 recall pertains to the system's built-in shielding and collimation accessories. 

Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.

Recor Medical's Paradise Ultrasound Renal Denervation System is the first medical device approved for the treatment of hypertension in Japan. It first gained FDA approval back in 2023.

Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%. 

The company describes Vivid Pioneer as its “most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet.” It includes new and improved AI capabilities and a compact design that is still fully functional in tight workspaces. 

Rad Partners "firmly" denied the allegations, which mirror a similar complaint from Aetna, contending it plans to "vigorously defend against these claims" in court.